Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of the Recombinant Human Anti-PD-1 Monoclonal Antibody for Subjects With Advanced Solid Tumors

NCT03713905 is registered in ClinicalTrials.gov with Guangzhou Gloria Biosciences Co., Ltd. as lead sponsor.

NCT NCT03713905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03713905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of the Recombinant Human Anti-PD-1 Monoclonal Antibody for Subjects With Advanced Solid Tumors
Lead sponsor
Guangzhou Gloria Biosciences Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
July 1, 2017
Completion date
February 28, 2022
Enrollment
293 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors